That is in excess of 95,000 alerts triggered a day, the figures from the Lucy Faithfull Foundation - the British charity that set up the system - shows. The alerts are sent when someone looks for child abuse content on platforms like TikTok, Meta products, ChatGPT, Google and pornography sites. The warning includes four key messages: viewing sexual images of children and having online sexual conversations with children is a crime, it causes harm to children, there are consequences for the offender, but there is help available to stop and change. "Tens of millions of people have been reached through just 22 targeted interventions on tech platforms," said Deborah Denis, chief executive at Lucy Faithfull Foundation. "That makes one thing clear - the potential to scale this approach is enormous. "By placing more warnings across more online spaces, we can disrupt harmful behaviour at the moment it's happening and prevent countless children from being harmed. "The need has never been more urgent, particularly as new AI technologies accelerate the spread of online child sexual abuse." From the tens of millions of alerts, just under 700,000 people followed links to further support, where they are encouraged to address their behaviour through online learning modules. One pornography site user said he found the modules after his searches triggered were useful. "I found the modules on addiction and pornography very helpful," he said. "About two months ago, I gave up those sites. I want to keep my mind occupied and more productive." Read more from Sky News:ChatGPT boss hits back at Elon MuskBodies of three women recovered from sea off Brighton There are ongoing efforts to tackle the growing problem of child sexual abuse crimes. Organisations like the Internet Watch Foundation track down and remove abusive imagery, and then tag the images so they can't be reuploaded, while more VPN companies are announcing they'll stop people accessing websites containing child sexual abuse material (CSAM). End-to-end encrypted services, where only the sender and recipient can see what is being sent, are often seen as a particularly difficult area to tackle when it comes to CSAM. However, the chief technology officer of Mega, an encrypted cloud storage provider that uses the alert system, said companies like his could take "meaningful action". "We recognised that it isn't enough to reactively or even proactively remove material, we alsoneeded to intervene earlier in the path towards harmful behaviour, before patterns become entrenched," said Andre Meister. "Through our work with Project Intercept, we are delivering well-timed deterrence messaging and self-help resourcing that interrupts harmful behaviour right at the point of intent, and we are pleased with the level of engagement the intervention has been driving. "It is a more complete, science-backed approach, and we are grateful for the partnership in our continued fight against CSAM."

Researchers have highlighted the orforglipron pill as a potentially "effective approach" for maintaining weight loss in people who don't want to or can't keep having the jabs. The drug, they say, is "significantly cheaper to manufacture" than the likes of Mounjaro and Wegovy and is also a GLP-1 agonist, a class of medication which helps to lower blood sugar levels, slow digestion, and reduce appetite. The daily pill - produced by Eli Lily, which funded the research - is not yet licensed in the UK, but was approved by the Food and Drug Administration in the US last month. A trial involved 376 people in the US who had been on tirzepatide or semaglutide - used for weight loss on the NHS under the brand names Wegovy and Mounjaro - for 72 weeks. Those patients were then given a daily pill of orforglipron or a placebo for a year. The study, published in Nature Medicine, found that among those who had been on tirzepatide, patients who shifted to orforglipron maintained 74.7% of their weight loss after a year, compared with 49.2% taking the placebo. Some 79.3% of former semaglutide users also maintained their weight loss, compared to 37.6% in the placebo group. The findings come after a previous study suggested people on the jabs were likely to regain the majority of weight lost within a year of stopping injecting. Read more from Sky News:The popular sandwiches with 'alarmingly high' salt content'Really significant moment' as Kate returns to world stage Reacting to the latest findings, Dr Marie Spreckley, research programme manager at the University of Cambridge, said: "One of the most valuable aspects of this study is that it reflects a highly realistic clinical scenario. "Many people do not want to remain on injectable therapy indefinitely due to treatment burden, convenience, travel, storage requirements, cost, or personal preference. "The possibility of transitioning to an oral therapy while maintaining a substantial proportion of the previously achieved weight reduction could therefore represent an important additional option within longer-term obesity care pathways." Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, noted that while patients lost more weight using injectable drugs, they are expensive. "This limits their long-term applicability both for private purchasers and the NHS," he said. "Newer, oral medications are significantly cheaper to manufacture, but do not tend to produce the same level of weight loss seen with injectable medications." He also said that while more research is needed with a larger group of patients, the findings point to "a potential future for how patients with obesity are treated, and how the success of weight loss can be maintained".

During the six-month-long pilot, live facial recognition (LFR) cameras in static locations were stationed on Croydon High Street, in south London, instead of on vans. Between October last year and March, the Metropolitan Police said 173 suspects were arrested for crimes including kidnapping, rape and serious sexual assault using the tech. Officers said the cameras were used in 24 operations, including the arrest of a 36-year-old woman who was wanted for failing to appear at court for an assault in 2004. The force also said a 31-year-old man who had been wanted for voyeurism for more than six months was arrested during the trial, as well as a 41-year-old man who was wanted over a rape in November. During the trial, the force added that crime in the area reduced by 10.5% and there was a 21% reduction in violence against women and girls. More than 470,000 people walked past the camera during the pilot. There was one false alert, where the person was spoken to by officers and then allowed to leave. See more from Sky News:Man shot dead by police in stand-offUK seizes thousands from US gangster Lindsey Chiswick, national and Met lead for live facial recognition, said the results of the trial "show why live facial recognition is such a powerful tool when it's used carefully, openly and in the right places". She added that "the public can see the difference", and said: "We will continue using static cameras in Croydon as part of our regular live facial recognition deployments, which play a vital part in keeping London safe." It comes after it was announced that facial recognition technology would be rolled out across the UK in April after a legal challenge against the Met from two claimants failed. Youth worker Shaun Thompson, one of the claimants, said he was misidentified by the technology used by the force. The other person bringing the claim was Silkie Carlo, from the group Big Brother Watch. Judges ruled the claimants' human rights had not been breached and the Met Police's policy gave an "adequate indication of the circumstances in which LFR will be used". They also said the argument the technology risked discriminating against people due to their race had not been convincing. Thirteen forces were using LFR by the end of last year, and the home secretary said in January the number of LFR vans would increase from 10 to 50. However, Essex Police paused its use of the technology earlier this year due to racial bias concerns.

Polycystic ovary syndrome (PCOS), a common condition that impacts how a woman's ovaries work, will now be referred to as polyendocrine metabolic ovarian syndrome (PMOS). PMOS is characterised by fluctuations in hormones, impacting weight, metabolic and mental health, skin, and the reproductive system. It is the most common cause of anovulation - where an egg does not release from the ovary during a menstrual cycle - among women globally and a leading cause of infertility, according to the World Health Organisation. Researchers and supporters of the change said the old name misrepresented what is a complex hormonal or endocrine disorder, often leading to a flawed focus on cysts and ovaries. The name change process, outlined on Wednesday in The Lancet, has taken 14 years of global collaboration between experts and those who have lived with the condition, which affects one in eight women worldwide. Professor Helena Teede, director of Monash University's Monash Centre for Health Research and Implementation in Australia, led the process after decades of research and seeing the old name's impact first-hand. "What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated," Professor Teede said. "It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded to those affected by this neglected condition." Professor Teede said it was the largest initiative to change the name of a medical condition, describing it as a "landmark moment" that will lead to worldwide advancements in clinical practice and research. "The agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and accompanying implementation," she said. What is PMOS? The three main features of PMOS are: irregular periods, excess androgen, and polycystic ovaries. Signs and symptoms usually become apparent during the late teens or early 20s. Read more from Sky News:The popular sandwiches with 'alarmingly high' salt content'Really significant moment' as Kate returns to world stage They can include: irregular periods or no periods at all, difficulty getting pregnant as a result of irregular ovulation or no ovulation, excessive hair growth, weight gain, thinning hair and hair loss from the head, and oily skin or acne. PMOS is also associated with a greater risk of developing health problems in later life, such as type 2 diabetes and high cholesterol levels. What causes the condition? The exact cause is unknown, but PMOS often runs in families, and it is related to abnormal hormone levels in the body, including high insulin levels. Many women with PMOS are resistant to the action of insulin and produce higher levels of insulin to counter this, contributing to the increased production and activity of hormones such as testosterone. How can PMOS be treated? There's no cure for PMOS, but symptoms can be treated. If you have it and you're overweight, losing weight and eating a healthy, balanced diet can help with some symptoms. There are also medicines available to treat individual symptoms, including excessive hair growth, irregular periods and fertility problems. A simple surgical procedure called laparoscopic ovarian drilling may be recommended if fertility medicines are not effective.

The two tech titans are at the centre of a California court battle over the firm behind ChatGPT. Mr Musk, who gave evidence last month, has accused Mr Altman, OpenAI and its president, Greg Brockman, of wooing millions of dollars from him between 2015 and 2017, when it was a non-profit, and then in 2019 moving to transform it into a corporate entity to enrich themselves. The launch of ChatGPT in 2022 transformed the company into one of the most powerful tech firms, and Mr Musk has suggested that the "not trustworthy" Mr Altman being in charge is "a very big danger for the whole world". Read more: The Altman vs Musk battle explained Under questioning in court on Tuesday, Mr Altman refuted the Tesla mogul's bid to paint him as unreliable. "I believe I am an honest and trustworthy businessperson," he said. Pressed on whether he had "misled people" while doing business, he replied: "I do not think so." Mr Altman also denied the accusation that he had tried to "steal a charity" with his leadership of OpenAI, which is preparing for a possible initial public offering that could value it at $1trn (£739bn). He said Mr Musk had not opposed the plan to create a for-profit arm of the firm in 2019, claiming the SpaceX boss knew about the plan before he quit the board the year before. He claimed Mr Musk once demanded a 90% stake in OpenAI, which made him feel "extremely uncomfortable". "I don't think Mr Musk understood how to run a good research lab," he added. "He had demotivated some of our most key researchers." Tap here for the latest science and tech news Testimony in the trial could conclude later this week, and jurors could begin deliberating whether the defendants are liable within days. Mr Musk, the world's richest person, wants $150bn (£111bn) in damages from OpenAI and investor Microsoft, to be paid into a non-profit, and wants Mr Altman and Mr Brockman removed from their roles. OpenAI claims he is only suing because he regrets leaving the board and missing out on potential riches.